# Antiviral Clinical Trial for Long Covid-19

> **NCT06511063** · PHASE2 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 90 (estimated)

## Conditions studied

- Long Covid

## Interventions

- **DRUG:** tenofovir disoproxil/emtricitabine
- **DRUG:** Selzentry
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06511063
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511063, "Antiviral Clinical Trial for Long Covid-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06511063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*